

PART I

STATEMENT OF STAND ALONE/CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER & NINE MONTHS ENDED 31.12.2012

Rs. in Lakhs

Particulars	Stand alone				Consolidated			
	Three months ended			Year Ended	Three months ended			Year Ended
	31.12.2012	30.09.2012	31.12.2011		31.12.2012	30.09.2012	31.12.2011	
	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Audited
1 Income from operations								
(a) Net sales/ income from operations (Net of excise duty)	141,263	137,248	118,072	389,767	313,245	420,461	155,195	148,105
(b) Other operating income	1,874	1,879	2,078	5,450	5,688	7,684	1,814	1,939
Total income from operations (net)	143,137	139,127	120,150	395,217	318,933	428,145	157,009	150,044
2 Expenses								
(a) Cost of material consumed	85,423	80,547	62,391	232,142	175,009	239,329	78,428	75,052
(b) Purchase of stock-in-trade	2,229	1,502	1,149	6,138	1,592	3,552	9,052	11,995
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(8,873)	(2,684)	5,205	(17,505)	8,497	8,987	(9,260)	(11,396)
(d) Employee benefits expense	10,995	10,809	9,377	32,016	27,284	36,410	16,682	16,703
(e) Depreciation and amortisation expense	4,224	4,213	3,601	12,541	10,456	14,294	6,079	5,983
(f) Provision for decline in the value of long-term investment	-	1,800	-	1,800	-	2,687	-	-
(g) Other expenses	25,113	23,431	20,470	70,118	57,418	77,681	36,197	32,662
Total expenses	119,111	119,618	102,193	337,250	280,256	382,940	137,178	130,999
3 Profit/(Loss) from operations before other income, finance costs, foreign exchange (gain)/loss and exceptional items (1-2)	24,026	19,509	17,957	57,967	38,677	45,205	19,831	19,045
4 Other income	108	622	211	838	1,076	1,906	564	659
5 Profit/(Loss) from ordinary activities before finance costs, foreign exchange (gain)/loss and exceptional items (3+4)	24,134	20,131	18,168	58,805	39,753	47,111	20,395	19,704
6 Finance costs (refer note 7)	2,850	2,999	2,494	8,879	6,061	9,311	3,312	3,350
7 Foreign exchange (Gain)/Loss (refer note 7)	6,496	(12,485)	14,638	13,336	29,208	19,596	7,336	(11,767)
8 Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6-7)	14,788	29,617	1,036	36,590	4,484	18,204	9,747	28,121
9 Exceptional item	-	-	-	-	31,986	31,986	1	12
10 Profit/(Loss) from ordinary activities before tax (8-9)	14,788	29,617	1,036	36,590	(27,502)	(13,782)	9,746	28,109
11 Tax expense/(credit)	360	5,816	(257)	3,345	(14,449)	(9,521)	646	5,913
12 Net Profit/(Loss) for the period (10-11)	14,428	23,801	1,293	33,245	(13,053)	(4,261)	9,100	22,196
13 Minority Interest	-	-	-	-	-	-	(81)	(39)
14 Net Profit/(Loss) after taxes and minority interest (12-13)	14,428	23,801	1,293	33,245	(13,053)	(4,261)	9,181	22,235
15 Paid-up Equity Share Capital (Face value Re. 1 per share)	2,911	2,911	2,911	2,911	2,911	2,911	2,911	2,911
16 Reserves excluding Revaluation Reserve	4,96	8,17	0.44	11.42	(4.48)	(1.46)	3.15	7.64
17 Earnings per share of Re.1/- each (not annualised)								
(a) Basic	4.96	8.17	0.44	11.42	(4.48)	(1.46)	3.15	7.64
(b) Diluted	4.96	8.17	0.44	11.42	(4.48)	(1.46)	3.15	7.64



28

SELECT INFORMATION FOR THE QUARTER & NINE MONTHS ENDED 31.12.2012



NOTES:

- 1 The above unaudited financial results as reviewed by the Audit Committee has been approved by the Board at its meeting held on February 07, 2013. A Limited Review of the above stand alone financial results has been carried out by the Statutory Auditors.
- 2 The Consolidated financial results, which are optional, have been presented by the Company, so as to provide additional information.
- 3 The consolidated financial results have been prepared in accordance with AS - 21 on 'Consolidated Financial Statement' and AS-27 'Financial Reporting of Interests in Joint Ventures' and includes financial results of all Subsidiaries and Joint Ventures.
- 4 The Company's operations fall within a single primary business segment viz. 'Pharmaceutical Products'.
- 5 Income from operations of standalone for the current quarter includes exports of Rs. 102,921 lakhs (Quarter ended December 31, 2011: Rs 88,511 lakhs).
- 6 Net sales for the current quarter include dossier income in standalone of Rs. 1,857 lakhs (Quarter ended December 31, 2011: Rs.2,064 lakhs) and in consolidated of Rs.3,855 lakhs (Quarter ended December 31, 2011 : Rs.2,276 lakhs).
- 7 Foreign exchange (gain)/loss for stand alone and consolidated includes exchange difference of Rs.4,999 lakhs, Rs.4,669 lakhs, Rs.4,586 lakhs for three months ended Dec 31, 2012, Sep 30, 2012 and Dec 31, 2011 respectively and Rs. 14,444 lakhs, Rs.12,658 lakhs for the nine months ended Dec 31, 2012 and Dec 31, 2011 respectively and Rs.17,447 lakhs for the year ended March 31, 2012 arising from foreign currency borrowings to the extent that they are regarded as an adjustment to finance cost as per para 4(e) of "AS 16" on Borrowing costs.
- 8 The results for the quarter in this statement have been reported in format recommended as per the SEBI circular dated April 16, 2012. Accordingly all other periods have also been restated to conform with the current period presentation.
- 9 The Board has approved an interim dividend @100% i.e. Re1/- (Rupee One only) per equity share of Re1/- (Rupee One only) for the year 2012-13.

Place: Hyderabad

Date : February 7, 2013

www.aurobindo.com

By Order of the Board

N. Govindarajan
Managing Director

